



GRANT CYCLE 5 (2018 -2020)

World Vision has partnered with the Global Fund since 2002, implementing grants across multiple allocation periods in diverse and often fragile contexts. This section highlights World Vision's programme coverage and engagement during Grant Cycle 5 (GC5), corresponding to the 2017–2019 allocation period, with grant implementation largely taking place between 2018 and 2020. Several GC5 grants received approved costed extensions, resulting in continued implementation into 2021 in selected countries to ensure completion of planned activities and achievement of programmatic results.


Highlights

In Grant Cycle 5 (GC5), World Vision managed a total Global Fund portfolio valued at USD 206,253,553 across malaria, tuberculosis, and HIV programmes. The portfolio comprised eight Principal Recipient (PR) awards implemented in seven countries, alongside fourteen Sub-Recipient and Sub-Sub-Recipient (SR/SSR) awards across nine countries. Through GC5-supported interventions, World Vision programmes reached over 70.2 million beneficiaries, the majority through malaria prevention and treatment activities (68.5 million), complemented by TB (444,931) and HIV (1.31 million) services.

Coverage

Disease Focus	PR – Countries	SR – Countries	SSR – Countries
Malaria	Mozambique; Malawi; Angola; Central African Republic	Kenya; Thailand	—
TB	Somalia; Nicaragua	Kenya; Thailand; Myanmar; India	Senegal
HIV	Nicaragua	Kenya; Haiti; Dominican Republic; Eswatini (Swaziland); Malawi; Zambia	—
HIV/TB	Papua New Guinea (PNG)	Thailand	—

Budget



Beneficiaries

Number of Beneficiaries - Malaria	68,475,700
Number of Beneficiaries - TB	44,4931
Number of Beneficiaries - HIV/TB	1,312,057
Total number of Beneficiaries	70,232,688

MALARIA FACT SHEET

During Grant Cycle 5 (GC5), World Vision served as a Principal Recipient (PR) of Global Fund–supported malaria grants in Mozambique, Malawi, Angola, and the Central African Republic, and as a Sub-Recipient (SR) in Kenya and Thailand. The malaria portfolio under GC5 was valued at USD 136.0 million and supported large-scale prevention and treatment interventions, reaching over 68.4 million beneficiaries between 2018 and 2020.

Coverage

Disease Focus	PR – Countries	SR – Countries	SSR – Countries
Malaria	Mozambique; Malawi; Angola; Central African Republic	Kenya; Thailand	—

Beneficiaries

Indicator	2018	2019	2020	Total
Case Management / Testing				
Total number of suspected malaria cases that received a parasitological test in the community or at the public health facilities	3,215,202	2,082,026	3,519,420	8,816,648
Treatment				
Confirmed malaria cases that received first line anti-malarial treatment (community and public health facilities)	1,187,058	1,449,913	5,684,232	8,321,203
Pregnant women who received 3 doses of IPTp	52,257	65,290	74,257	191,804
Vector Control				
LLIN distributed (Mass + Continuous)	11,210,674	5,587,429	13,844,425	30,642,528
Structures sprayed with IRS	142,070	225,503	836,370	1,203,943
Beneficiaries				
# Direct Beneficiaries	23,456,959	22,776,652	22,242,089	68,475,700

HIV FACT SHEET

In Grant Cycle 5 (GC5), World Vision's HIV/AIDS portfolio included both HIV and integrated HIV/TB programmes across multiple regions. World Vision served as a Principal Recipient (PR) for integrated HIV/TB programming in Papua New Guinea and for HIV programming in Nicaragua, while supporting HIV and HIV/TB programmes as a Sub-Recipient (SR) in Kenya, Haiti, the Dominican Republic, Eswatini (Swaziland), Malawi, Zambia, and Thailand. The GC5 HIV portfolio was valued at USD 40.4 million and reached over 1.3 million beneficiaries during the 2018–2020 implementation period

Coverage

Disease Focus	PR – Countries	SR – Countries
HIV	Nicaragua	Kenya; Haiti; Dominican Republic; Eswatini ; Malawi; Zambia
HIV/TB	Papua New Guinea (PNG)	Thailand

Beneficiaries

Indicator	2018	2019	2020	Total
Prevention				
Key population reached with defined package of services	22,992	41,893	49,816	114,701
Testing				
Women and men aged 15+ who received an HIV test and know their results	27,132	30,055	28,552	85,739
Treatment				
PLHIV newly linked to treatment, care and support, including ART	26,697	12,930	442	40,069
Adults and children currently receiving antiretroviral therapy	445	30,757	33,861	65,063
Education				
Number of young people aged 10-24 years reached by life skills-based HIV education in and out of schools	170,484	441,876	130,033	742,393
Beneficiaries				
# Direct Beneficiaries	331,251	571,534	409,272	1,312,057

TB FACT SHEET

During Grant Cycle 5 (GC5), World Vision implemented tuberculosis (TB) programmes across multiple high-burden settings, serving as a Principal Recipient (PR) in Somalia and Nicaragua, as a Sub-Recipient (SR) in Kenya, Thailand, Myanmar, and India, and as a Sub-Sub-Recipient (SSR) in Senegal. The GC5 TB portfolio was valued at USD 29.8 million and supported TB prevention, diagnosis, and treatment services, reaching approximately 445,000 beneficiaries during the 2018–2020 implementation period

Coverage

Disease Focus	PR – Countries	SR – Countries	SSR – Countries
TB	Somalia; Nicaragua	Kenya; Thailand; Myanmar; India	Senegal

Beneficiaries

Indicator	2018	2019	2020	Total
TB & MDR TB Case Detection and Notification				
Number of notified cases of all forms of TB	31,781	63,276	81,835	176,892
Number of case of RR and/or MDR-TB reported	747	1,332	1,094	3,173
Treatment Success Rate				
Treatment success rate - all forms	78	N/A	N/A	78
Number of people enrolled in DOT (adults and children)	16,405	17,061	17,486	50,952
TB Preventive Therapy				
Number of children <5 in contact with TB patients who began IPT	426	802	804	2,032
HIV/TB				
TB patients with documented HIV status	22,089	N/A	30,347	52,436
Beneficiaries				
# Direct Beneficiaries	55,836	214,190	174,905	444,931